Empagliflozin is under clinical development by Boehringer Ingelheim International and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData, Phase II drugs for Pulmonary ...

Highlighted text has been updated as of December 20, 2024. The EMPA-KIDNEY trial showed that empagliflozin has salutary effects on renal function and CV mortality among patients with CKD, with or ...

GoodRx Holdings (GDRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 16. Analyst Michael Cherny from Leerink Partners reiterated a Buy ...

More than a year after its co-founders left the company, GoodRx will have a new president and CEO. On Monday, the consumer drug pricing and digital health company announced Wendy Barnes will take ...

You are responsible for reading, understanding, and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy ...

1. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383(15):1413–24. 2. McMurray JJV, Solomon SD, Inzucchi SE, et al.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...